ECSP19081847A - Método para preparar intermedio de derivado de 4-metoxipirrol - Google Patents

Método para preparar intermedio de derivado de 4-metoxipirrol

Info

Publication number
ECSP19081847A
ECSP19081847A ECSENADI201981847A ECDI201981847A ECSP19081847A EC SP19081847 A ECSP19081847 A EC SP19081847A EC SENADI201981847 A ECSENADI201981847 A EC SENADI201981847A EC DI201981847 A ECDI201981847 A EC DI201981847A EC SP19081847 A ECSP19081847 A EC SP19081847A
Authority
EC
Ecuador
Prior art keywords
preparing
metoxypirrol
derivative intermediate
present
inexpensive
Prior art date
Application number
ECSENADI201981847A
Other languages
English (en)
Inventor
Jeong-Taek Shin
Seung Chul Lee
Jeong Hyun Son
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of ECSP19081847A publication Critical patent/ECSP19081847A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método para preparar productos intermedios de derivados de 4-metoxipirrol. El método de preparación según la presente invención tiene las ventajas de que el coste de producción puede reducirse usando materiales de partida económicos, no se requiere una elevada temperatura de reacción en su totalidad, se usan reactivos económicos y no explosivos en lugar de (trimetilsilil)diazometano, y puede prepararse además un producto intermedio de derivados de 4-metoxipirrol en su totalidad a un alto rendimiento.
ECSENADI201981847A 2017-06-21 2019-11-15 Método para preparar intermedio de derivado de 4-metoxipirrol ECSP19081847A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170078745A KR102233455B1 (ko) 2017-06-21 2017-06-21 4-메톡시피롤 유도체의 중간체 제조 방법

Publications (1)

Publication Number Publication Date
ECSP19081847A true ECSP19081847A (es) 2019-11-30

Family

ID=64735783

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201981847A ECSP19081847A (es) 2017-06-21 2019-11-15 Método para preparar intermedio de derivado de 4-metoxipirrol

Country Status (30)

Country Link
US (2) US11345660B2 (es)
EP (1) EP3642181B1 (es)
JP (1) JP6799178B2 (es)
KR (1) KR102233455B1 (es)
CN (1) CN110582482B (es)
AU (1) AU2018288933B2 (es)
BR (1) BR112019027323A2 (es)
CA (1) CA3061713C (es)
CL (1) CL2019003450A1 (es)
CO (1) CO2019012689A2 (es)
DO (1) DOP2019000291A (es)
EC (1) ECSP19081847A (es)
ES (1) ES2901701T3 (es)
HR (1) HRP20211819T1 (es)
HU (1) HUE057666T2 (es)
JO (1) JOP20190265B1 (es)
MA (1) MA49472B1 (es)
MY (1) MY188800A (es)
NZ (1) NZ758770A (es)
PE (1) PE20210151A1 (es)
PH (1) PH12019502865A1 (es)
PL (1) PL3642181T3 (es)
PT (1) PT3642181T (es)
RS (1) RS62564B1 (es)
RU (1) RU2737470C1 (es)
SA (1) SA519410407B1 (es)
SG (1) SG11201911164WA (es)
SI (1) SI3642181T1 (es)
TN (1) TN2019000301A1 (es)
WO (1) WO2018236153A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
US10789690B2 (en) * 2018-03-07 2020-09-29 Adobe Inc. Masking non-public content
CN109867617A (zh) * 2019-04-03 2019-06-11 南京格亚医药科技有限公司 一种4-甲氧基吡咯中间体的制备方法
CN112094219B (zh) * 2020-09-10 2022-08-05 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
CN117326961B (zh) * 2023-09-27 2024-05-03 安徽峆一药业股份有限公司 一种非苏拉赞中间体的绿色合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
JP5173192B2 (ja) 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
RS52473B9 (sr) 2005-08-30 2019-07-31 Takeda Pharmaceuticals Co 1-heterociklilsulfonil, 2-aminometil, 5-(hetero-)aril supstituisani derivati 1-h-pirola kao inhibitori sekrecije kiseline
KR101174191B1 (ko) * 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린
CN102088855A (zh) * 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
US8895558B2 (en) * 2008-10-02 2014-11-25 Green Cross Corporation Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20170113040A (ko) * 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
KR102081920B1 (ko) * 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
WO2017164575A1 (en) * 2016-03-25 2017-09-28 Daewoong Pharmaceutical Co.,Ltd. Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine
KR102233456B1 (ko) 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) * 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Also Published As

Publication number Publication date
EP3642181A4 (en) 2020-12-09
CO2019012689A2 (es) 2020-01-17
US20220259146A1 (en) 2022-08-18
CA3061713C (en) 2021-10-12
CA3061713A1 (en) 2018-12-27
PE20210151A1 (es) 2021-01-26
AU2018288933A1 (en) 2019-11-21
CN110582482B (zh) 2022-10-11
AU2018288933B2 (en) 2020-12-10
WO2018236153A1 (en) 2018-12-27
JOP20190265B1 (ar) 2023-03-28
DOP2019000291A (es) 2019-12-15
RU2737470C1 (ru) 2020-11-30
PH12019502865A1 (en) 2020-12-07
SI3642181T1 (sl) 2022-04-29
HRP20211819T1 (hr) 2022-03-04
JOP20190265A1 (ar) 2019-11-12
MA49472B1 (fr) 2022-01-31
CN110582482A (zh) 2019-12-17
US11345660B2 (en) 2022-05-31
MY188800A (en) 2022-01-04
KR102233455B1 (ko) 2021-03-29
JP2020519680A (ja) 2020-07-02
NZ758770A (en) 2022-01-28
KR20180138476A (ko) 2018-12-31
US20200181080A1 (en) 2020-06-11
PL3642181T3 (pl) 2022-02-14
SG11201911164WA (en) 2020-01-30
SA519410407B1 (ar) 2022-06-14
ES2901701T3 (es) 2022-03-23
PT3642181T (pt) 2021-12-20
TN2019000301A1 (en) 2021-05-07
EP3642181A1 (en) 2020-04-29
BR112019027323A2 (pt) 2020-07-28
CL2019003450A1 (es) 2020-03-27
RS62564B1 (sr) 2021-12-31
EP3642181B1 (en) 2021-11-03
JP6799178B2 (ja) 2020-12-09
MA49472A (fr) 2020-04-29
HUE057666T2 (hu) 2022-06-28

Similar Documents

Publication Publication Date Title
ECSP19081847A (es) Método para preparar intermedio de derivado de 4-metoxipirrol
DOP2019000292A (es) Método para preparar intermedio de derivado de 4-metoxipirrol
PH12018500093A1 (en) Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
BR112017022488A2 (pt) produção microbiana de terpenoides
BR112015031233A2 (pt) métodos de produção de derivados de ácidos graxos omega-hidroxilados
CL2018003602A1 (es) Proceso para preparar almidón hidrolizado con contenido de azúcar reducido.
BR112017000876A2 (pt) ?processo de fabricação de uma peça feita de material compósito de matriz de cerâmica, peça feita de material compósito de matriz de cerâmica, e, motor de turbina?
MX2020004869A (es) Metodo para preparar derivado de benzofurano.
EA201690696A1 (ru) Способ получения адамантанамидов
BR112016025024A2 (pt) ?processo para preparar compostos ceto, e, uso de farnesil acetona?
WO2015120111A3 (en) Expedient synthesis of sitagliptin
BR112014014762A2 (pt) método para preparação de cisteína ou de um derivado desta usando uma nova o-fosferina sulfidrilase
AR098879A1 (es) Síntesis de ent-progesterona y sus productos intermedios
MX2018010128A (es) Toxina nueva y metodo de preparacion de un intermediario de la misma.
WO2015114518A3 (en) Procedure for the preparation of abiraterone acetate and intermediates thereof
BR112018004854A8 (pt) Processo para a produção de hidrolisado dessalinizado de biomassa, hidrolisado dessalinizado preparado pelo dito processo e uso do dito hidrolisado dessalinizado como um meio de fermentação
BR112015026740A2 (pt) método para sintetizar derivados de furano, e, método para preparar derivados de furano
BR112017004368A2 (pt) ?micro-organismo com produtibilidade de l-lisina aprimorada e método para produzir l-lisina com o uso do mesmo?.
BR112022007354A2 (pt) Processo para síntese de picolinamidas
PL407240A1 (pl) Sposób wytwarzania (2S,4S)-cis-flawan-4-olu
CA2935504C (en) Synthesis method of 9-allylcamptothecin derivatives
BR112017019116A2 (pt) método para preparar composto de sulfonamida de alta pureza e intermediário do composto de sulfonamida
TH168117A (th) จุลชีพที่รีคอมบิแนนท์ที่มีการแสดงออกของอะเวอร์เมคตินอะนาล็อก และการใช้ของพวกมัน